Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins

Triple-negative breast cancer (TNBC) constitutes 10%–15% of all breast tumors. The current standard of care is multiagent chemotherapy, which is effective in only a subset of patients. The original objective of this study was to deploy a mass spectrometry (MS)-based kinase inhibitor pulldown assay (...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Junkai, Saltzman, Alexander B., Jaehnig, Eric J., Lei, Jonathan T., Malovannaya, Anna, Holt, Matthew V., Young, Meggie N., Rimawi, Mothaffar F., Ademuyiwa, Foluso O., Anurag, Meenakshi, Kim, Beom-Jun, Ellis, Matthew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10426551/
https://www.ncbi.nlm.nih.gov/pubmed/37587913
http://dx.doi.org/10.1158/2767-9764.CRC-22-0501

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10426551/
https://www.ncbi.nlm.nih.gov/pubmed/37587913
http://dx.doi.org/10.1158/2767-9764.CRC-22-0501

Ejemplares similares